In summary, hybrid hydrogel dressings may constitute biocompatible materials that effectively promote the treatment of diabetes by effectively silencing the MMP-9 gene, providing a platform for siRNA applications in other diseases. This evidence concerns the gene MMP9 and diabetes mellitus.